1. Home
  2. AMPH vs PHAT Comparison

AMPH vs PHAT Comparison

Compare AMPH & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amphastar Pharmaceuticals Inc.

AMPH

Amphastar Pharmaceuticals Inc.

HOLD

Current Price

$19.03

Market Cap

971.8M

Sector

Health Care

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$10.93

Market Cap

894.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMPH
PHAT
Founded
1996
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
971.8M
894.0M
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
AMPH
PHAT
Price
$19.03
$10.93
Analyst Decision
Buy
Strong Buy
Analyst Count
8
6
Target Price
$28.38
$19.83
AVG Volume (30 Days)
614.5K
996.2K
Earning Date
05-07-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
42.72
EPS
0.14
N/A
Revenue
$719,887,000.00
$175,110,000.00
Revenue This Year
$6.90
$93.04
Revenue Next Year
$4.64
$58.91
P/E Ratio
$139.07
N/A
Revenue Growth
N/A
216.93
52 Week Low
$16.65
$7.61
52 Week High
$31.26
$18.31

Technical Indicators

Market Signals
Indicator
AMPH
PHAT
Relative Strength Index (RSI) 45.67 51.98
Support Level $18.92 $10.02
Resistance Level $19.81 $12.99
Average True Range (ATR) 0.76 0.65
MACD 0.08 0.17
Stochastic Oscillator 41.78 81.49

Price Performance

Historical Comparison
AMPH
PHAT

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: